Aptose Biosciences Inc. 8-K

What Happened
Aptose Biosciences Inc. announced on May 29, 2026 that it issued a press release, and the company filed an 8‑K (Item 7.01) to disclose that release. The press release is attached to the filing as Exhibit 99.1. The 8‑K notes the press release is furnished under Regulation FD and, per Form 8‑K instructions, is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act and is not incorporated by reference into other filings unless expressly stated.

Key Details

• Filing date: May 29, 2026 (Form 8‑K filed with the SEC).
• Item reported: 7.01 (Regulation FD Disclosure) — press release attached as Exhibit 99.1.
• Legal note: Information in the press release is furnished (not “filed”) and not automatically incorporated by reference into other SEC filings.
• Exhibit list (Item 9.01): Exhibit 99.1 (press release) and an Inline XBRL interactive data file included.

Why It Matters
This 8‑K indicates Aptose made a public disclosure via press release on May 29, 2026. For investors, the material content and any potentially market‑moving details are in Exhibit 99.1; review that press release (available on EDGAR or the company website) to learn specifics such as results, guidance, or corporate updates. The Reg FD designation signals the company intended the information to be broadly available to the public, while the filing language clarifies certain legal limits on incorporation and liability.